Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0031154 (
peritonitis
)
15,372
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Leukocyte mono-Ig-like receptor 5
(
LMIR5
, also called
CD300b
) is an activating receptor expressed in myeloid cells. We have previously demonstrated that T cell Ig mucin 1 works as a ligand for
LMIR5
in mouse ischemia/reperfusion injury of the kidneys. In this article, we show that
LMIR5
is implicated in LPS-induced sepsis in mice. Notably, neutrophils constitutively released a soluble form of
LMIR5
(sLMIR5) through proteolytic cleavage of surface
LMIR5
. Stimulation with TLR agonists augmented the release of sLMIR5. LPS administration or
peritonitis
induction increased serum levels of sLMIR5 in mice, which was substantially inhibited by neutrophil depletion. Thus, neutrophils were the main source of LPS-induced sLMIR5 in vivo. On the other hand, i.p. administration of
LMIR5
-Fc, a surrogate of sLMIR5, bound to resident macrophages (M) and stimulated transient inflammation in mice. Consistently,
LMIR5
-Fc induced in vitro cytokine production of peritoneal M via its unknown ligand. Interestingly,
LMIR5
deficiency profoundly reduced systemic cytokine production and septic mortality in LPS-administered mice, although it did not affect in vitro cytokine production of LPS-stimulated peritoneal M. Importantly, the resistance of
LMIR5
-deficient mice to LPS- or
peritonitis
-induced septic death was decreased by
LMIR5
-Fc administration, implicating sLMIR5 in LPS responses in vivo. Collectively, neutrophil-derived sLMIR5 amplifies LPS-induced lethal inflammation.
...
PMID:A soluble form of LMIR5/CD300b amplifies lipopolysaccharide-induced lethal inflammation in sepsis. 2277 46